DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/01/21

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close. The consensus EPS Estimate is -$1.25 (-10.6% Y/Y) and the consensus Revenue Estimate is $23.57M (+52.6% Y/Y). Over the last 3 months, EPS estimates have seen 0 up...

Tango Therapeutics (NASDAQ:TNGX) has appointed Marc Rudoltz as the company’s new Chief Medical Officer. An alumnus of the Massachusetts Institute of Technology (MIT) and SUNY-Upstate Medical University, Rudoltz has over 20 years of experience in leading clinical-stage drug develop...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 ...

If you're looking for stocks that can make big moves on a relatively predictable timeline, the biotechnology space has you covered. Hardly a day goes by where you don't see at least one stock from this industry rocket higher, or crash and burn. Right now, investors are waiting for n...

– Seventh Approval Worldwide for QINLOCK and First European Approval – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced t...

– DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell Lung Cancer Cell Lines and Decrease Tumor Burden in Combination with Osimertinib and Afatinib in EGFR Mutant Xenograft Model – Deciphera Pharmace...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event. For further details see: Deciphera Pharmaceuticals (DCPH) ESMO 2021Virtual Congress Presentation - Slideshow

– European Commission Decision Anticipated by the Fourth Quarter of 2021 – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announc...

– Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients with Platinum-Resistant Ovarian Cancer (PROC) – – Pivotal Phase 3 Study of Rebastinib plus Paclitaxel in PROC Planned to Initiat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...